EAU 2024 - The 39th Annual European Association of Urology Congress 2024
Apr 05 - Apr 08, 2024 | ParisFrance
LARVOL is not affiliated with The 39th Annual European Association of Urology Congress 2024 and all trademarks, logos, and brand names are property of their respective owners
Showing 12 titles linked to Trials
External validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in a sexual majority and minority population following robotic prostatectomy (RARP): NCT05772598
Screen E: Prostate cancer Enzalutamide (enza) with or without leuprolide in patients (pts) with European Association of Urology (EAU)-guideline-defined high-risk biochemically recurrent prostate cancer (BCR) following radical prostatectomy (RP) or radiation therapy (RT): EMBARK post hoc analysis
Screen D: Post-prostatectomy ED and rehabilitation Low-intensity extracorporeal shockwave therapy is safe immediately following robotic-assisted radical prostatectomy (NCT03862599)
Clinical trials in muscle-invasive bladder cancer Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer (CNN-BC trial).
Results from SunRISe-1 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 monotherapy
SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer
Three-year oncological outcomes of the randomized phase II trial ARNEO: Neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer.
Two-year quality of life (QoL) outcomes of the randomized phase II trial ARNEO: neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer
PSICHE trial (NCT05022914): PSMA guided approach for bIochemical relapse after prostatectomy- a prospective trial
Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
Screen D: Trials in progress WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.
No clinical benefit from Sequential Combination of Mitomycin C Plus Bacillus Calmette- Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial (NCT03790384)